What this means
This trial is still recruiting people, and no results have been posted yet. It will test whether the drug empagliflozin lowers arterial stiffening over 12 weeks.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 60–80 · 80 adults aged 60 to 80
- Where
- 1 site, including Missouri
The science
- Registered title
- Empagliflozin Reversal of Arterial StiffnEss in Aging
- Trial ID
- NCT06506422 ↗
- Phase
- PHASE 2 / PHASE 3
- Study type
- interventional
- Conditions
- Aging, Arterial Stiffness
- What is tested
- Empagliflozin 10 MG, Placebo
- Sponsor
- University of Missouri-Columbia
- Ages
- 60 Years to 80 Years
- Dates
- First posted Jul 17, 2024 · updated Feb 6, 2026
Registry summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Sites (1)
- University of Missouri, Columbia, Missouri, United States